ByteDance's AI drug development unit has begun separation and independent financing, with ByteDance retaining controlling equity. The new entity will include core team, algorithms, platform, and pipeline assets, led by the original team, and will continue to receive computing support from Volcano Engine. Established in 2021 with about 50 members, this move marks the transition of ByteDance's AI4S business from internal incubation to market-oriented operations, potentially accelerating AI applications in biopharma.